About Tumor necrosis factor alpha-induced protein 8-like protein 1
Tumor necrosis factor alpha-induced protein 8-like protein 1 (TNFAIP8L1) is a protein
from Homo sapiens identified by UniProt accession
Q8WVP5, 186 residues long.
MolForge cross-references it against 0 known binders and
94 disease associations.
Target properties
| Protein name | Tumor necrosis factor alpha-induced protein 8-like protein 1 |
|---|
| UniProt accession | Q8WVP5 |
|---|
| Gene | TNFAIP8L1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 186 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (94)
Diseases linked to this target (Open Targets).
- neoplasm · score 0.10
- inflammatory bowel disease · score 0.09
- cancer · score 0.09
- diffuse large B-cell lymphoma · score 0.08
- liver dysplastic nodule · score 0.07
- Autosomal recessive early-onset inflammatory bowel disease · score 0.06
- type 2 diabetes mellitus · score 0.06
- immunodeficiency due to MASP-2 deficiency · score 0.05
- gastroesophageal reflux disease · score 0.05
- neuronal ceroid lipofuscinosis 1 · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8WVP5-F1 | alphafold | PREDICTED | 90.76 | — |
Amino-acid sequence (186 residues)
MDTFSTKSLA LQAQKKLLSK MASKAVVAVL VDDTSSEVLD ELYRATREFT RSRKEAQKML KNLVKVALKL GLLLRGDQLG GEELALLRRF RHRARCLAMT AVSFHQVDFT FDRRVLAAGL LECRDLLHQA VGPHLTAKSH GRINHVFGHL ADCDFLAALY GPAEPYRSHL RRICEGLGRM LDEGSL
Explore Tumor necrosis factor alpha-induced protein 8-like protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets